Zobrazeno 1 - 10 of 136 pro vyhledávání: '"Gram-Nielsen S"'
1
Akademický článek
Cyclic Citrullinated Peptide Aptamer Treatment Attenuates Collagen-Induced Arthritis.
Autor: Khatri S; Department of Chemistry, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Hansen J; Department of Chemistry, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Pedersen NB; Department of Chemistry, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Brandt-Clausen IP; DTU Biofacility, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Gram-Nielsen S; DTU Biofacility, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Mendes AC; DTU FOOD, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Chronakis IS; DTU FOOD, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Keiding UB; Center for Nanomedicine and Theranostics, Department of Chemistry, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Catrina AI; Department of Medicine/Solna, Division of Rheumatology, Karolinska Institute and Karolinska University Hospital, Stockholm 164 90, Sweden., Rethi B; Department of Medicine/Solna, Division of Rheumatology, Karolinska Institute and Karolinska University Hospital, Stockholm 164 90, Sweden., Clausen MH; IBIO TECH ApS, Copenhagen 2450, Denmark.; Center for Nanomedicine and Theranostics, Department of Chemistry, Technical University of Denmark, Kgs Lyngby 2800, Denmark., Kragstrup T; IBIO TECH ApS, Copenhagen 2450, Denmark.; Department of Biomedicine, University of Aarhus, Aarhus C 8000, Denmark., Astakhova K; Department of Chemistry, Technical University of Denmark, Kgs Lyngby 2800, Denmark.; IBIO TECH ApS, Copenhagen 2450, Denmark.
Publikováno v: Biomacromolecules [Biomacromolecules] 2022 May 09; Vol. 23 (5), pp. 2126-2137. Date of Electronic Publication: 2022 Apr 19.
Zobrazit plný text záznamu
2
Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability
Autor: Gradel, A. K. J., Porsgaard, T., Lykkesfeldt, J., Seested, T., Gram-Nielsen, S., Kristensen, N. R., Refsgaard, H. H. F.
Publikováno v: Journal of Diabetes Research.
Variability in the effect of subcutaneously administered insulin represents a major challenge in insulin therapy where precise dosing is required in order to achieve targeted glucose levels. Since this variability is largely influenced by the absorpt
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=hindawi_publ::7b70641e02cb7f668f44259c55f60a47
Zobrazit plný text záznamu
3
Akademický článek
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans.
Autor: Kjeldsen TB; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hubálek F; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hjørringgaard CU; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Tagmose TM; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Nishimura E; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Stidsen CE; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Porsgaard T; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Fledelius C; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Refsgaard HHF; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Gram-Nielsen S; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Naver H; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Pridal L; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hoeg-Jensen T; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Jeppesen CB; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Manfè V; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Ludvigsen S; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Lautrup-Larsen I; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Madsen P; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Jul 08; Vol. 64 (13), pp. 8942-8950. Date of Electronic Publication: 2021 May 04.
Zobrazit plný text záznamu
4
Akademický článek
Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320.
Autor: Kjeldsen TB; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hubálek F; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Tagmose TM; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Pridal L; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Refsgaard HHF; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Porsgaard T; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Gram-Nielsen S; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hovgaard L; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Valore H; Novo Nordisk A/S, CMC API Development, Brudelysvej 20, DK-2880 Bagsvaerd, Denmark., Münzel M; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hjørringgaard CU; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Jeppesen CB; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Manfè V; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Hoeg-Jensen T; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Ludvigsen S; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Nielsen PK; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Lautrup-Larsen I; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Stidsen CE; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Wulff EM; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Garibay PW; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Kodra JT; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Nishimura E; Novo Nordisk A/S, Global Drug Discovery, Novo Nordisk Park, DK-2760 Maaloev, Denmark., Madsen P; Novo Nordisk A/S, Global Research Technologies, Novo Nordisk Park, DK-2760 Maaloev, Denmark.
Publikováno v: Journal of medicinal chemistry [J Med Chem] 2021 Jan 14; Vol. 64 (1), pp. 616-628. Date of Electronic Publication: 2020 Dec 28.
Zobrazit plný text záznamu
5
Author Correction: Molecular engineering of safe and efficacious oral basal insulin.
Autor: Hubálek F; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Refsgaard HHF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Gram-Nielsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Madsen P; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nishimura E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Münzel M; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Brand CL; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Stidsen CE; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Claussen CH; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Wulff EM; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Pridal L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ribel U; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Kildegaard J; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Porsgaard T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Johansson E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Steensgaard DB; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hovgaard L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Glendorf T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hansen BF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Jensen MK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nielsen PK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ludvigsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Rugh S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Garibay PW; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Moore MC; Vanderbilt University, Nashville, TN, USA., Cherrington AD; Vanderbilt University, Nashville, TN, USA., Kjeldsen T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark. ThK@novonordisk.com.
Publikováno v: Nature communications [Nat Commun] 2020 Aug 20; Vol. 11 (1), pp. 4232. Date of Electronic Publication: 2020 Aug 20.
Zobrazit plný text záznamu
6
Akademický článek
Molecular engineering of safe and efficacious oral basal insulin.
Autor: Hubálek F; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Refsgaard HHF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Gram-Nielsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Madsen P; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nishimura E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Münzel M; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Brand CL; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Stidsen CE; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Claussen CH; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Wulff EM; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Pridal L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ribel U; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Kildegaard J; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Porsgaard T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Johansson E; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Steensgaard DB; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hovgaard L; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Glendorf T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Hansen BF; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Jensen MK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Nielsen PK; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Ludvigsen S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Rugh S; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Garibay PW; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark., Moore MC; Vanderbilt University, Nashville, TN, USA., Cherrington AD; Vanderbilt University, Nashville, TN, USA., Kjeldsen T; Novo Nordisk A/S, Novo Nordisk Park 1, 2760, Maaloev, Denmark. ThK@novonordisk.com.
Publikováno v: Nature communications [Nat Commun] 2020 Jul 27; Vol. 11 (1), pp. 3746. Date of Electronic Publication: 2020 Jul 27.
Zobrazit plný text záznamu
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
Akademický článek
Insulin resistance assessed by short insulin tolerance test and its association with obesity and insulin resistance-related parameters in humans: A pilot randomized trial.
Autor: Hayashishita, Akiko1 (AUTHOR), Watanabe, Taku1 (AUTHOR) taku.watanabe@gmail.com, Suzuki, Naoko1 (AUTHOR), Nakaya, Toshitaka1 (AUTHOR), Sugimoto, Ayako1 (AUTHOR), Yokota, Isao2 (AUTHOR), Ohira, Hiroshi1 (AUTHOR), Nishimura, Masaharu1 (AUTHOR), Tsujino, Ichizo1 (AUTHOR)
Publikováno v: PLoS ONE. 6/21/2024, Vol. 19 Issue 6, p1-11. 11p.
Zobrazit plný text záznamu
9
Akademický článek
Which Diabetes Patients Will Benefit the Most from Once-Weekly Basal Insulin Analogs? A Review with a Special Focus on Type 1 Diabetes Patients.
Autor: Kosmeri, Chrysoula1 (AUTHOR) chrisa.kosmeri@gmail.com, Baltogianni, Maria2 (AUTHOR) mbalt@doctors.org.uk, Giapros, Vasileios2 (AUTHOR) faybal18@yahoo.com, Siomou, Ekaterini1 (AUTHOR) eksiomou@uoi.gr, Tsinopoulou, Vasiliki-Regina3 (AUTHOR) vasotsino@gmail.com, Balomenou, Foteini2 (AUTHOR), Serbis, Anastasios1 (AUTHOR) tasos_serbis@yahoo.com
Publikováno v: Endocrines. Jun2024, Vol. 5 Issue 2, p214-224. 11p.
Zobrazit plný text záznamu
10
Akademický článek
Pharmacological and Benefit-Risk Profile of Once-Weekly Basal Insulin Administration (Icodec): Addressing Patients' Unmet Needs and Exploring Future Applications.
Autor: Ingrasciotta, Ylenia1,2 (AUTHOR) ylenia.ingrasciotta@univr.it, Vitturi, Giacomo1 (AUTHOR) giacomo.vitturi@univr.it, Trifirò, Gianluca1,2 (AUTHOR) gianluca.trifiro@univr.it
Publikováno v: Journal of Clinical Medicine. Apr2024, Vol. 13 Issue 7, p2113. 17p.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje